Foundayo is Eli Lilly's brand name for orforglipron, the first small-molecule GLP-1 pill approved for obesity. The FDA cleared it in early April 2026; the IQVIA launch tracker has stepped up from 3,707 prescriptions in Week 2 to 5,612 in Week 3 to 7,335 in Week 4 (the week ending May 1, per Citi's May 8 client note). Citi flagged that the IQVIA data captures retail and partial telehealth, likely understating Lilly Direct and the 12+ telehealth firms that account for roughly 35% of launch volume — Lilly executives have cited 20,000 patients now on the drug. Citi modeled $146M in Q2 and $1.6B for full-year 2026. On the April 30 Q1 call, Lilly disclosed more than 8,000 prescribers (one-third writing an oral GLP-1 for the first time) and 80% of patients new to the GLP-1 class — with commercial access confirmed at two of the three largest US PBMs effective mid-May.
The ACHIEVE-3 obesity Phase 3 gave Foundayo HbA1c superiority versus oral semaglutide in type-2 diabetes, but indirect comparisons published just after launch suggested oral Wegovy may produce greater weight loss with fewer GI discontinuations. Managed Healthcare Executive's head-to-head writeup framed the choice as HbA1c lead versus weight-loss lead. On May 4, an FAERS hepatic-failure case in a 56-year-old male — logged April 30 — surfaced publicly. LLY fell 3% premarket before recovering as Lilly released updated safety data the FDA had requested, citing no DILI signal across the 11,000-patient ACHIEVE+ATTAIN program. RBC Capital framed the case as 'baseline noise' and pointed to comparable hepatic-failure tallies for Mounjaro (30), Ozempic (33), Wegovy (15), and Zepbound (2).
Stories here cover prescription volumes, payer coverage, head-to-head comparisons with oral Wegovy, and side-effect signals from FAERS. See #orforglipron for the underlying molecule and #oral-glp-1 for class context.
Endpoints News published a mid-year FDA review Wednesday reporting that the FDA cleared 23 novel drugs through June 30, 2026, the best first half of a year for novel approvals since 2023. The pace held up despite the Trump administration's April 2025 FDA staff cuts that industry observers had feared would slow the approval machine. Total regulatory verdicts in H1 2026 ran 79 (slight decrease from 85 in H1 2025), but novel approvals ticked up substantially from 19 in H1 2025 to 26 by the Endpoints tally (approaches vary slightly by definition; the FDA's Novel Drug Approvals for 2026 tracker shows 23 through the June 30 cutoff). Approvals during the period spanned oncology, infectious disease, nephrology, dermatology, ophthalmology, and metabolic disease. The peptide-relevant approvals within this pace include Yuviwel (navepegritide, Ascendis Pharma's once-weekly C-type natriuretic peptide prodrug for pediatric achondroplasia; accelerated approval February 27), Foundayo (orforglipron, Eli Lilly's oral small-molecule GLP-1 for chronic weight management; April 1), Tryngolza (olezarsen, Ionis's ASO for severe hypertriglyceridemia; June 24), and Trutakna (atacicept, Vera Therapeutics' BAFF/APRIL fusion protein for IgA nephropathy; July 7). The staff-cut concern has partially receded, though longer-term impacts on Center for Drug Evaluation and Research (CDER) throughput remain a Q3-Q4 2026 story to watch.
The Centers for Medicare and Medicaid Services' Medicare GLP-1 Bridge demonstration program launched Wednesday July 1, 2026, opening prior-authorization submissions through Humana as central processor and activating the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR). The program provides eligible Medicare Part D beneficiaries with $50/month access to four FDA-approved obesity drugs: Foundayo (orforglipron oral tablets, Eli Lilly), Wegovy injection (semaglutide, Novo Nordisk), Wegovy tablets (oral semaglutide in 1.5, 4, 9, and 25 mg strengths), and Zepbound KwikPen (tirzepatide single-dose autoinjector, Eli Lilly). CMS targets 72-hour prior-authorization turnaround. The Bridge runs through December 31, 2027 and transitions to the broader BALANCE Model launching January 2027 in Part D. It represents the first time Medicare has helped pay for drugs prescribed solely for obesity, breaking the 2003 Medicare Modernization Act exclusion that had barred obesity-only prescriptions from Part D coverage.
The Medicare GLP-1 Bridge demonstration program launches Wednesday July 1, 2026 (one day from this digest), providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen through December 31, 2027. Operationally, Humana opens its central-processor function for prior-authorization submissions and claims adjudication starting tomorrow; the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR) become active for first fills. Walgreens published pharmacist-navigation guidance Tuesday flagging that store pharmacists will help Medicare patients verify eligibility (the three-tier BMI-and-comorbidity criteria walked through in this site's June 29 patient-guide insight), confirm Part D enrollment status, and submit the Bridge prior-authorization request to Humana through the dedicated workflow. CNN published a June 29 consumer explainer flagging that the program is the first time Medicare has paid for drugs prescribed solely for obesity. The Bridge runs in parallel with the broader BALANCE Model launching January 2027 in Part D, with the Bridge ending December 31, 2027 and beneficiaries transitioning to BALANCE.
The Centers for Medicare & Medicaid Services' Medicare GLP-1 Bridge demonstration launches Wednesday July 1, 2026, five days from this digest's publication, providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen) for chronic weight management through December 31, 2027. Humana is the single central processor for prior authorization, claims adjudication, and pharmacy payment, operating outside of the standard Part D benefit's coverage and payment flow (Part D sponsors do not carry risk for eligible GLP-1 drugs under the Bridge). Two procedural details for prescribers: Medicare enrollment is not required to write a prescription or submit a prior-authorization request under the Bridge (the provider just cannot be on the Preclusion List), and prior-authorization requests will not be accepted or processed before July 1, when the prior-authorization form will be updated to include the fax submission number. Eligibility runs through three BMI tiers: BMI ≥35 with no additional requirement; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; or BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease. The Bridge bridges to the broader BALANCE Model launching January 2027 in Medicare Part D.
Hims & Hers' proxy report ahead of the June 11 virtual annual meeting shows 2025 revenue at $2.35 billion (up 59%), 2.5 million-plus subscribers, $318 million adjusted EBITDA, and $300 million operating cash flow. The company's GLP-1 pivot now leans on the Lilly tie-up (Zepbound vials and KwikPens, plus Foundayo via LillyDirect; Bank of America lifted its price target to $32) and the renewed Novo Nordisk partnership for branded Wegovy. The compounded-semaglutide business is winding down ahead of the FDA 503B exclusion that becomes effective after the June 29 comment window closes.
Lilly presented full Phase 3 data from the ACHIEVE program in type 2 diabetes at ADA 2026's Monday symposium. In the head-to-head ACHIEVE-3 trial, Foundayo (orforglipron) beat oral semaglutide across the primary and all key secondary endpoints, with 37.1% of patients on the highest Foundayo dose reaching HbA1c under 5.7% (normal range) versus 12.5% on the highest oral semaglutide dose tested. ACHIEVE-2 compared Foundayo to dapagliflozin; ACHIEVE-5 added it to insulin glargine. Lilly plans to submit Foundayo for FDA T2D approval by end of Q2 under the Commissioner's National Priority Voucher.
Eli Lilly will present full data on retatrutide, Foundayo (orforglipron), and Mounjaro at the American Diabetes Association's 86th Scientific Sessions. The triple agonist retatrutide lowered A1C by up to 2.0% and drove 16.8% weight loss, about 36.6 lbs at the 12 mg dose, over 40 weeks in its first Phase 3 diabetes trial, TRANSCEND-T2D-1. Oral Foundayo beat oral semaglutide head-to-head with 73.6% greater relative weight loss and an A1C reduction of up to 1.7% against 0.8% for dapagliflozin.
Published May 12 in Nature Medicine and presented at ECO 2026, the first-of-its-kind ATTAIN-MAINTAIN trial (NCT06584916) tested whether adults who had already lost substantial weight on Wegovy or Zepbound could maintain it after switching to once-daily orforglipron. Over 52 weeks, the semaglutide-switch group regained an average of 1 kg and the tirzepatide-switch group an average of 5 kg, with most cardiometabolic gains preserved. Carel le Roux and Louis Aronne led the analysis.
IQVIA's weekly prescription tracker for Foundayo (orforglipron) hit approximately 17,000 prescriptions for the week ending May 15, 2026, per Citi's Friday client note — Lilly's first above-15,000 weekly print since the April 6 launch. The week-by-week trajectory: 1,390 (Week 1), 3,707 (Week 2), 5,612 (Week 3), 7,335 (Week 4), 10,248 (Week 5), and ~17,000 in the new print. Novo Nordisk's Wegovy pill recorded roughly 142,000 prescriptions in the same week — the trajectory gap is narrowing as Foundayo's PBM coverage activates at the largest US plans but still remains 8.3x the Foundayo volume. Citi maintains $146M Foundayo Q2 revenue and $1.6B 2026 full-year estimates; the IQVIA print supports the trajectory. Lilly's late-May TV-advertising launch may amplify the next leg of Foundayo growth heading into mid-June.
Novo Nordisk's Executive Vice President for International Operations Emil Kongshøj Larsen told CNBC May 18 the company is preparing to go 'all in' on launching its Wegovy pill outside the US, with UK, Germany, and Denmark at the front of the international queue. The company disclosed cumulative US Wegovy pill prescriptions have crossed 2 million in the 18 weeks since the January 5 launch — roughly double the >1M figure CEO Maziar Doustdar shared on May 14. Larsen's quote: 'When we launch, we'll go all in.' The international expansion lands as Novo's full-year 2026 guidance still calls for revenue and profit declines between 4% and 12%, but the company hiked guidance slightly last week after Q1 oral semaglutide sales beat expectations. The international Wegovy pill timing matters for Lilly's Foundayo (orforglipron), which had its US PBM coverage activate mid-May but has no near-term international launch date.
The CNBC May 18 piece surfaced explicit company-supported positioning that Foundayo (orforglipron) and oral Wegovy are targeting different patient segments rather than competing head-to-head. Novo's framing for Wegovy pill is 'injectable-like efficacy' in oral form, with the Phase 3 OASIS-MAINTAIN data anchoring approximately 15% mean weight loss. Lilly's framing for Foundayo positions it as more of a 'starter' GLP-1 — lower weight-loss ceiling (around 11.2% in ATTAIN-1) but no food-or-water dosing restrictions and a non-peptide small-molecule manufacturing path that supports a lower long-term price. Both companies say the pills are expanding the market rather than significantly cannibalizing demand for the injectables — a different framing than the 'oral-disrupts-injectable' narrative that dominated 2025 coverage. The market-expansion hypothesis will be testable as ADA 2026 (June 5-8) and Q2 2026 earnings prints land.
Fierce Pharma's Oral GLP-1 Tracker reported the first weekly decline in Wegovy pill prescriptions since the January 5, 2026 launch: scripts dropped from ~143,000 to ~137,000 in the week ending May 8. Total Wegovy (injectable + pill) scripts climbed 1.3% w/w to ~446,000, taking obesity GLP-1 market share to 40.5%. Eli Lilly's Foundayo posted Week 5 IQVIA prescriptions of 10,248, up 40% w/w from Week 4's 7,335 — the steepest weekly growth in the launch series, attributed to mid-May commercial access activation at two of the three largest US PBMs. The cumulative US Wegovy pill user count crossed 1 million per Novo CEO Doustdar's May 14 commentary; the Wegovy injectable continues to be the largest US GLP-1 single-product line. The Wegovy pill plateau and Foundayo acceleration narrow the trajectory gap that has defined the oral-GLP-1 race since April.
Eli Lilly executives confirmed on the April 30 Q1 call that a full direct-to-consumer TV advertising campaign for Foundayo (orforglipron) launches in late May 2026, coinciding with the mid-May commercial access activation at two of the three largest US pharmacy benefit managers. The campaign emphasizes Foundayo's only-oral-GLP-1-without-food-or-water-restrictions positioning vs Novo's Wegovy pill, which requires fasting administration. Lilly previously held back consumer advertising through the first six weeks of launch to let PBM coverage scale before driving consumer prescription demand. Citi's May 8 IQVIA note flagged the upcoming campaign and PBM expansion as the catalysts for the Week 5+ trajectory acceleration that landed in the May 8 IQVIA print (10,248 scripts, +40% w/w).
Citi's Friday May 15 client note reported Foundayo (orforglipron) hit 10,248 US prescriptions in the week ending May 8 per IQVIA — the first 40% week-over-week jump in the launch series. Week-by-week trajectory: 1,390 (Week 1), 3,707 (Week 2), 5,612 (Week 3), 7,335 (Week 4), 10,248 (Week 5). The acceleration aligns with mid-May commercial access activation at two of the three largest US PBMs that Lilly flagged on the April 30 Q1 call. Citi maintained $146M Q2 revenue and $1.6B full-year 2026 estimates. The Wegovy pill remains ahead — Novo CEO Doustdar's May 14 commentary confirmed >1M cumulative US users since the January 5 launch — but the gap is narrowing as Foundayo's PBM coverage comes online and telehealth volume (~35% of total per Lilly executives, not captured in retail-only IQVIA data) layers on top.
Eli Lilly executives' Q1 commentary clarified the Foundayo launch-channel mix: roughly 45% via LillyDirect (the company's direct-to-patient pharmacy), 35% via telehealth platforms not captured in retail-only IQVIA data, and 20% via traditional retail pharmacy fills. The split helps explain the apparent gap between Citi's IQVIA-reported 10,248 Week 5 prescriptions and the 20,000+ patient count Lilly disclosed on the April 30 Q1 call. The pattern suggests Foundayo is being adopted preferentially through digitally-enabled care channels — Hims & Hers, LifeMD, JoinFound, and other telehealth platforms with weight-management Rx infrastructure — rather than primary-care prescribing. The mix is structurally similar to the Wegovy pill launch but with a higher telehealth share. The implication for the next 90 days: PBM coverage expansion (mid-May) and brand-name TV advertising (launching late May per the Q1 commentary) will drive most of the next leg of growth.
The next Foundayo IQVIA prescription tracker update is expected from Citi mid-week May 18-20, covering the week ending May 8. Week 4 hit 7,335 prescriptions per the May 8 Citi note with Lilly executives citing 20,000 total patients (~35% via telehealth not captured in the retail-only IQVIA data). Citi's projected $146M Q2 revenue and $1.6B full-year 2026 estimate continue to anchor the analyst consensus. Lilly executives have asked analysts for 8-12 weeks of data before reading commercial trajectory through pharmacy-fill noise; the Week 5 reading is the first post-PBM-coverage-expansion data point as the two largest US PBMs went live with Foundayo coverage mid-May. The Wegovy pill remains roughly 60-70x ahead on weekly volume (>440K in the week ending May 1 per Novo's Q1 commentary).
Eli Lilly published SURMOUNT-MAINTAIN in The Lancet and ATTAIN-MAINTAIN in Nature Medicine on May 12, with concurrent presentation at ECO 2026 in Istanbul. SURMOUNT-MAINTAIN tested lower-dose Zepbound (tirzepatide 5 mg) vs maximum tolerated dose: at week 112, MTD preserved all weight loss while the 5 mg arm lost only 5.6 kg additional. ATTAIN-MAINTAIN tested Foundayo (orforglipron) as a switch from injectable GLP-1s in SURMOUNT-5 participants: orforglipron preserved 79.3% of injectable-phase weight loss vs 37.6% on placebo at week 52; Wegovy MTD switchers regained only 0.9 kg, Zepbound MTD switchers regained 5.0 kg. The dual readout reframes the maintenance-versus-discontinuation conversation: dose-tapering and oral-switching strategies now have Phase 3 evidence behind them, validating the long-term-treatment chronic-disease framing.
An ORION indirect treatment comparison presented at ECO 2026 on May 13 framed the head-to-head competition between Novo's Wegovy pill (oral semaglutide 25 mg) and Lilly's Foundayo (orforglipron 36 mg). The Wegovy pill delivered statistically significant greater mean weight loss than orforglipron, with patients on orforglipron showing approximately 14x higher odds of discontinuing treatment due to gastrointestinal side effects. The May 13 framing complements Novo's Q1 print disclosure that Wegovy holds 65% of all new US GLP-1 prescriptions; CEO Mike Doustdar's CNBC commentary called the moment a 'turnaround situation' for the Danish company. The ORION ITC matters as a prescriber-decision tool given the two compounds are now the only two FDA-approved oral GLP-1s for chronic weight management.